Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease

Movement Disorders

Volumn 27, Issue 4, 2012, Pages 559-561

  Di Giacopo, Raffaella ^a,b   Fasano, Alfonso ^a,c   Quaranta, Davide ^a   Marca, Giacomo Della ^a   Bove, Francesco ^a   Bentivoglio, Anna Rita ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Achille e Linda Lorenzon Foundation   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Cholinesterase inhibitors; REM behavior disorder (RBD)

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; LEVODOPA; MELATONIN; PLACEBO; RIVASTIGMINE;

AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PILOT STUDY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM BEHAVIOR DISORDER; REM SLEEP; SLEEP DISORDER; TREATMENT OUTCOME;

AGED; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHENYLCARBAMATES; PILOT PROJECTS; POLYSOMNOGRAPHY; REM SLEEP BEHAVIOR DISORDER;

EID: 84859423506     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24909     Document Type: Article

References (14)

1. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
2. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspective 16 years after its formal identification in sleep. Sleep 2002; 25: 120-138.
3. Boeve BF, Silber MH, Saper CB, et al. Patophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770-2788.
4. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
5. Diederich NJ, Goetz CG, Stebbins GT, et al. Repeated visual hallucinations in Parkinson's disease as a disturbed external/internal perception: focused review and a new integrative model. Mov Disord 2005; 2: 130-140.
6. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology. 2000; 55: 281-288.
7. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Eng J Med 2004; 351: 2509-2518.
8. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonism psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1771-1774
9. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55: 870-871.
10. Omerovic M, Teipel SJ, Hampel T. Dementia with Lewy bodies. Clinical improvement under treatment with acetylcholinesterase inhibitor [Abstract]. Nervenarzt 2007; 78: 1052-1057.
11. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Dis 2006; 21: 1899-1907.
12. Anderson KN, Phil D, Shneerson JM. Drug Treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009; 5: 235-239
13. Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology 1992; 42: 1371-1374.
14. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 2nd ed. (ICSD-2). Diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, Westchester; 2006.